The Filing Desk

Celularity vs Scynexis

Celularity CELU · Scynexis SCYX · Pharmaceuticals

Celularity reported revenue of $26 million in fiscal 2025, 1.3 times Scynexis' $21 million in fiscal 2025. Celularity's revenue fell 51.0% in its latest year, and Scynexis' grew 449.9%. Celularity had an operating margin of -230.9%, against -78.0% at Scynexis.

Side by side

CelularityScynexis
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$26M$21M
Revenue growth−51.0%449.9%
Revenue growth a year, last 5 years13.1%—
Gross margin24.4%—
Operating margin−230.9%−78.0%
Net margin−345.4%−41.8%
Free cash flow——
Free cash flow margin——
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count16.9%2.9%
Last close$0.47$2.60
P/E at the last close——
Insider trades, last 12 months——
Piotroski F-score—4 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
CelularityScynexis
Operating margin
Percent of revenue
CelularityScynexis
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
CelularityScynexis

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Celularity and Scynexis pages.